In this episode of Blue Collar ICs, the crew tackles one of the biggest questions in interventional cardiology right now:
Is Impella dead?
Following the latest trial data presented at ACC, including DTU and BSIS-3, the discussion dives deep into what the results actually mean—and what they don’t. Featuring insights from Dr. Amir Kaki and longtime industry expert Jim Schubert, the conversation explores the gap between clinical trials and real-world practice.
From bleeding complications and patient selection to high-risk PCI strategy and cardiogenic shock, this episode breaks down where Impella fits today—and where it’s headed next.
The takeaway? The data may be mixed, but the story is far from over.
","author_name":"RealWorks Media"}